R&D Center
Pre-IND
Phase I
Phase II
Phase III
Registration
Marketed
Hematology
Ropeginterferon alfa-2b
PV (EU, CH, IL)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA
Hematology
Ropeginterferon alfa-2b
PV (TW, KR)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA
Hematology
Ropeginterferon alfa-2b
PV (US)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA
Hematology
Ropeginterferon alfa-2b
PV (JP, CN)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA
Hematology
Ropeginterferon alfa-2b
ET (Global)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA
Hematology
Ropeginterferon alfa-2b
Adult T-cell Leukemia (JP, TW, CN)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA
Hematology
Ropeginterferon alfa-2b (next generation)
MPN (Global)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA
Oncology
Ropeginterferon alfa-2b+anti PD-1
HCC (Global)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA
Oncology
Oraxol
Breast Cancer (TW, SG, VN, JP, KR)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA
Oncology
Oraxol + Ramucirumab
Gastric Cancer (TW, SG, VN)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA
Oncology
Ropeginterferon alfa-2b
Solid Tumors (Global)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA
Infectious Disease
Ropeginterferon alfa-2b
HDV (US, EU, TW)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA
Dermatology
KX01
Psoriasis (TW, CN, MO, SG, JP, KR)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA
Dermatology
KX01
Actinic Keratosis (TW, JP, KR)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA